This website uses cookies, which are necessary for the technical operation of the website and are always set. Other cookies, which increase the comfort when using this website, are used for direct advertising or to facilitate interaction with other websites and social networks, are only set with your consent.
Configuration
Technically required
These cookies are necessary for the basic functions of the shop.
"Allow all cookies" cookie
"Decline all cookies" cookie
CSRF token
Cookie preferences
Currency change
Customer-specific caching
FACT-Finder tracking
Individual prices
Selected shop
Session
Comfort functions
These cookies are used to make the shopping experience even more appealing, for example for the recognition of the visitor.
Note
Show the facebook fanpage in the right blod sidebar
Statistics & Tracking
Affiliate program
Conversion and usertracking via Google Tag Manager
Zonisamide is a broad-spectrum sulfonamide antiepileptic agent. It selectively blocks the repeated firing of sodium channels (IC50 = 2 µg/ml) at low concentrations in mouse embryo spinal cord neurons, and it blocks spontaneous channel firing at concentrations above 10 µg/ml. In rat cerebral cortex neurons, zonisamide (1-1000 µM) dose-dependently blocks T-type calcium channels with a maximum reduction of 60% of the calcium current. Zonisamide inhibits recombinant H. pylori carbonic anhydrase (CA) and human CA isoforms I, II, and V with Ki values of 218, 56, 35, and 21 nM, respectively. Zonisamide has anticonvulsant activity in rats, rabbits, dogs, and mice with a potency similar to phenobarbital (Cay-9001494) and carbamazepine in maximal electroshock seizure (MES) models. In mice, it has anticonvulsant activity against MES and pentylenetetrazole-induced maximal and minimal seizures with median effective doses of 19.6, 9.3, and >500 mg/kg, respectively. Zonisamide (10-100 mg/kg, p.o.) dose-dependently prevents reduction of dopamine (Cay-21992), homovanillic acid (HVA), and dihydroxyphenyl acetic acid (DOPAC) levels and the elevation of the dopamine turnover rate induced by MPTP in mouse striatum. Formulations containing zonisamide have been used in the treatment of partial seizures in adults with epilepsy.Formal Name: 1,2-benzisoxazole-3-methanesulfonamide. CAS Number: 68291-97-4. Synonyms: CI-912, PD 110843. Molecular Formula: C8H8N2O3S. Formula Weight: 212.2. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMSO: <100 mM, Water: <10 mM. lambdamax: 238, 284 nm. SMILES: NS(CC1=NOC2=CC=CC=C21)(=O)=O. InChi Code: InChI=1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12). InChi Key: UBQNRHZMVUUOMG-UHFFFAOYSA-N.
This website uses cookies, which are necessary for the technical operation of the website and are always set. Other cookies, which increase the usability of this website, serve for direct advertising or simplify interaction with other websites and social networks, will only be used with your consent.
More information